



Superior Dyes for **Superior Data**

FOR IMMEDIATE RELEASE

NIRvana Sciences Awarded Phase II SBIR Grant from NIGMS

RESEARCH TRIANGLE PARK, NC, JUNE 1, 2022 – NIRvana Sciences, Inc., the leading developer of synthetic bacteriochlorins and chlorins, today announced that it has been awarded a Phase I SBIR grant from the National Institute for General Medical Sciences (NIGMS) at the National Institutes of Health (NIH).

This two-year, Phase II grant titled, “Fluorescent Nanofoldamers for Multiplex Flow Cytometry,” will be used to complete development and commercialize NIRvana’s proprietary, ultra-small particle platform into the cytometry market.

“This new ultra-small particle probe platform will enable NIRvana to bring forth its brightest offerings as well as further expand reagent color portfolios by bringing new classes of dyes into the field of cytometry and other life science applications and markets” says CEO Russell Thomas.

About NIRvana Sciences

NIRvana Sciences is a spin-out from North Carolina State University with a mission to commercialize red and near-infrared fluorescent dyes and associated probes with narrow spectral properties for use in life science applications. In addition to support from NIH, NIRvana has also received support from angel investors in North and South Carolina, North Carolina Biotechnology Center (NCBC), NC IDEA and Blackstone Entrepreneurs Network. NIRvana facility is located at Alexandria Innovation Center in Research Triangle Park, NC USA.

For additional information, please visit www.nirvanasciences.com

Contact:

NIRvana Sciences, Inc.

Russell Thomas

919.354.1053

Russell@nirvanasciences.com
